Hyperfine, Inc. has gained FDA approval for its latest software update, integrating advanced AI algorithms to enhance image quality across all sequences of its portable magnetic resonance brain imaging system, the Swoop. This update focuses on improving diffusion-weighted imaging (DWI) while expanding AI denoising capabilities. These enhancements aim to provide crisper images, facilitating more accurate diagnosis and treatment monitoring in time-sensitive medical environments. Hyperfine’s dedication to innovation and accessibility is evident, with its eighth FDA clearance in three years, emphasizing its commitment to reshaping patient care and advancing brain imaging technology. The updated software will be available in the coming months.
Hyperfine, Inc., a pioneering medical technology company at the forefront of redefining brain imaging through the groundbreaking Swoop system – the world’s first FDA-cleared portable magnetic resonance brain imaging system – has officially received FDA clearance for its latest software update. This state-of-the-art software leverages the power of advanced artificial intelligence (AI) algorithms to introduce substantial improvements in image quality, particularly within the Swoop system’s diffusion-weighted imaging (DWI) sequence.
With this software upgrade, Hyperfine, Inc. has extended the AI-driven denoising capabilities to the DWI sequence, augmenting an already robust feature set. Previous iterations of the system’s sequences, including T1, T2, and FLAIR, had already witnessed the advantages of AI-driven denoising. This enhancement results in crisper images, potentially aiding healthcare professionals in more accurate diagnoses, treatment planning, and patient monitoring during brain imaging procedures.
Tom Teisseyre, the Chief Operating Officer of Hyperfine, Inc., emphasized the company’s commitment to making brain imaging more accessible, clinically relevant, and actionable. “We are continually advancing across all sequences, and this latest update introduces deep learning into our DWI sequence,” he stated. “These enhancements in imaging quality will play a crucial role in supporting healthcare professionals, especially in time-sensitive scenarios.”
Maria Sainz, the President and CEO of Hyperfine, Inc., highlighted the company’s remarkable achievements. “Securing our eighth FDA software clearance in just three years for the Swoop system underscores our relentless dedication to innovation and constant improvement. Our primary focus remains on delivering high-quality brain imaging solutions to an ever-expanding network of healthcare providers and patients across diverse care settings. It’s not just about reaching milestones; it’s about reshaping patient care, empowering clinicians, and advancing the field of brain imaging.”
Hyperfine, Inc. is set to roll out the upgraded Swoop system software in the coming months, further reinforcing its commitment to pushing the boundaries of brain imaging technology.
